Table 3.

Outcomes for Prespecified Endpoints: Symptoms Resolution for Patients with COVID-19 Treated with Monoclonal Antibodies

Variable	All Patients(n = 321)	Bamlanivimab(n = 201)	Casirivimab/ Imdevimab(n = 120)	Relative Risk Ratio(95% CI), p Value
Day 5 after infusion How bad are your symptoms today? Patients that reported no symptoms, n (%) How is your general health today? Patients that reported excellent health (score 5), n (%) Have you returned to your usual (pre-COVID) health today? Yes, n (%)	4 (4–5) 92/306 (30.1) 4 (3–4) 76/307 (24.8) 96/307 (31.2)	4 (4–5) 51/188 (27.1) 4 (3–4) 46/189 (24.3) 58/189 (30.7)	4 (4–5) 41/118 (34.7) 4 (3–5) 30/118 (25.4) 38/118 (32.2)	— 0.87 (0.69–1.05), 0.16 — 0.97 (0.78–1.18), 0.80 1.01 (0.86–1.16), < 0.99
Day 10 after infusion How bad are your symptoms today? Patients that reported no symptoms (score 5), n (%) How is your general health today? Patients that reported excellent health, n (%) Have you returned to your usual (pre-COVID) health today? Yes, n (%)	5 (4–5) 180/316 (56.9) 4 (4–5) 144/316 (45.6) 180/316 (56.9)	5 (4–5) 114/199 (57.3) 4 (4–5) 91/199 (45.7) 116/199 (58.3)	5 (4–5) 66/117 (56.4) 4 (4–5) 53/117 (45.2) 64/117 (54.7)	— 1.01 (0.86–1.21), 0.91 — 1.01 (0.84-1.19), > 0.99 1.06 (0.89-1.26), 0.56

CI = confidence interval; COVID-19 = coronavirus disease 2019.

Patient self-assessment of symptoms improvement was evaluated at day 5 and day 10 after antibody administration. The following three questions were employed: “Overall, how bad your symptoms were today?” Answers: 1 very severe, 2 severe, 3 moderate, 4 mild, 5 no symptoms,” “Overall, how is your general health today?” Answers: 1 poor, 2 fair, 3 good, 4 very good, 5 excellent. “Have you returned to your usual (pre-COVID) health today?” Answers: yes or no.